NCT00363454View on ClinicalTrials.gov

Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Cancer
Interventions
DRUG

Triciribine Phosphate Monohydrate

8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Insitute, Tampa

Sponsors
All Listed Sponsors
collaborator

VioQuest Pharmaceuticals

INDUSTRY

lead

Prescient Therapeutics, Ltd.

INDUSTRY

NCT00363454 - Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer | Biotech Hunter | Biotech Hunter